Evercore analyst Liisa Bayko maintains $Intellia Therapeutics (NTLA.US)$ with a buy rating, and adjusts the target price from $70 to $60.
According to TipRanks data, the analyst has a success rate of 45.3% and a total average return of 10.2% over the past year.
Furthermore, according to the comprehensive report, the opinions of $Intellia Therapeutics (NTLA.US)$'s main analysts recently are as follows:
An analyst noted that Intellia Therapeutics' recent Phase 2 data for NTLA-2002 showed a reduction in attacks that was somewhat less impressive than the Phase 1 outcomes for HAE presented earlier. The data indicated an attack reduction that aligns with what competitors have seen in Phase 3 trials. The analyst highlighted the unique advantage of NTLA-2002's potential as a one-time treatment compared to competitors that require more frequent dosing. Despite this, expectations for the peak market share of NTLA-2002 have been moderated, along with the probability of success for NTLA-2001 in ATTR, suggesting that further platform validation is necessary.
The firm's perspective on Intellia Therapeutics has become incrementally negative after evaluating the results of the Phase 2 study of NTLA-2002 in patients with hereditary angioedema (HAE).
Note:
TipRanks, an independent third party, provides analysis data from financial analysts and calculates the Average Returns and Success Rates of the analysts' recommendations. The information presented is not an investment recommendation and is intended for informational purposes only.
Success rate is the number of the analyst's successful ratings, divided by his/her total number of ratings over the past year. A successful rating is one based on if TipRanks' virtual portfolio earned a positive return from the stock. Total average return is the average rate of return that the TipRanks' virtual portfolio has earned over the past year. These portfolios are established based on the analyst's preliminary rating and are adjusted according to the changes in the rating.
TipRanks provides a ranking of each analyst up to 5 stars, which is representative of all recommendations from the analyst. An analyst's past performance is evaluated on a scale of 1 to 5 stars, with more stars indicating better performance. The star level is determined by his/her total success rate and average return.
Evercore分析師Liisa Bayko維持$Intellia Therapeutics (NTLA.US)$買入評級，並將目標價從70美元下調至60美元。
根據TipRanks數據顯示，該分析師近一年總勝率為45.3%，總平均回報率為10.2%。
此外，綜合報道，$Intellia Therapeutics (NTLA.US)$近期主要分析師觀點如下：
一位分析師指出，Intellia Therapeutics最近關於NTLA-2002的2期數據顯示，攻擊性減少的情況略遜於之前提出的HAE的1期結果。數據顯示，攻擊性減少的情況與競爭對手在3期試驗中看到的情況一致。分析師還強調了NTLA-2002作爲一次性治療的獨特優勢，相較於需要更頻繁給藥的競爭對手。儘管如此，對於NTLA-2002的市場份額峯值預期已經被調整，以及NTLA-2001在ATTR中成功的概率，表明需要進一步驗證平台。
該公司對Intellia Therapeutics的觀點在評估了NTLA-2002在遺傳性血管性水腫（HAE）患者中2期研究結果後變得逐漸消極。
提示:
TipRanks為獨立第三方，提供金融分析師的分析數據，並計算分析師推薦的平均回報率和勝率。提供的信息並非投資建議，僅供参考。本文不對評級數據和報告的完整性與準確性做出認可、聲明或保證。
TipRanks提供每位分析師的星級，分析師星級代表分析師所有推薦的過往表現，通過分析師的總勝率和平均回報率综合計算得出，星星越多，則該分析師過往表現越優異，最高爲5颗星。
分析師總勝率為近一年分析師的評級成功次數占總評級次數的比率。評级的成功與否，取決於TipRanks的虚擬投資組合是否從該股票中產生正回報。
總平均回報率為基於分析師的初始評級創建虚擬投資組合，並根據評級變化對組合進行調整，在近一年中該投資組合所獲得的回報率。
